Localizzazione S1 di Herpes Zooster: un raro caso di ritenzione urinaria.

Donna di 46 anni con ritenzione urinaria acuta e stipsi. Presentava piccola vescicola sul dorso del piede sinistro quale unica manifestazione di localizzazione di virus Herpes Zooster a livello sacrale S1. Viene riportato l'esame urodinamico e le risultanze dei test sierologici seriati specifici per l'infezione da virus Varicella Zooster. La paziente è guarita a seguito di terapia specifica con Acyclovir. Il caso riportato dimostra che anche il segmento sacrale S1 contribuisce al controllo della dinamica minzionale

Fibronectin (FN), Epidermal Growth Factor-Receptor (EGF-R) and Heparin-Binding Epidermal Growth Factor-Like Growth Factor (HB-EGF) expressions in relation to toxicity of adjuvant intravesical therapy for non-muscle invasive bladder cancer.

AMYLOIDOSIS AND INFLAMMATORY BOWEL DISEASE: FACT OR MITH?

Inflammatory Bowel Disease (IBD), which includes both Crohn's Disease (CD) and Ulcerative Colitis (UC), is a chronic idiopathic inflammatory disorder affecting the gastrointestinal tract. Extraintestinal manifestations (EIM) are common in patients with IBD, and occur in 6-47% of patients with CD or UC. EIM can involve organs other than the gastrointestinal tract such as skin, eyes, joints, biliary tract and kidneis. Renal and urinary involvement particularly occurs in 4-23% of patients with IBD. Among the renal complications of IBD, seconfary amyloidosis (AA-type, AAA) is a rare but serious complication. renal amyloidosis has been proven to be the most common lethal manifestation of IBD-ass…

COMPLIANCE WITH ONE YEAR MAINTENANCE INTRAVESICAL BCG IN PATIENTS AFFECTED BY T1G3 BLADDER CANCER

Introduction: BCG maintenance for at least one year is the best regimen for prevention of recurrence and progression in high risk non muscle invasive bladder cancer (NMIBC), undergoing conservative approach. Noteworthy, a relevant number of patients do not complete the planned treatment interruption. Study aim was to analyze retrospectively the reasons of treatment. Patients and Methods: Consecutive patients affected by T1G3 BC, undergoing BCG maintenance for one year, according to the SWOG schedule (3 weekly instillations at 3, 6, 12 months) were included in this study. Connaught BCG (81 mg/50 ml) was given starting 1430 days after TUR. If toxicity occurred, treatment was postponed up to t…